lifibrate: hypolipemic, hypocholesteremic agent; minor descriptor (75-82); online & Index Medicus search GLYCOLATES (75-82) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 31060 |
| CHEMBL ID | 1883563 |
| SCHEMBL ID | 666775 |
| MeSH ID | M0262453 |
| Synonym |
|---|
| 1-methylpiperidin-4-yl 2,2-bis(4-chlorophenoxy)acetate |
| lifibratum [inn-latin] |
| acetic acid, bis(4-chlorophenoxy)-, 1-methyl-4-piperidinyl ester |
| einecs 244-839-2 |
| glyoxylic acid, 1-methyl-4-piperidyl ester, 2-(bis(p-chlorophenyl) acetal) |
| lifibrate [usan:inn] |
| sah-42-348 |
| 1-methyl-4-piperidyl glyoxylate 2-(bis(p-chlorophenyl) acetal) |
| lifibrato [inn-spanish] |
| sah-2348 |
| acetic acid, bis(p-chlorophenoxy)-, 1-methyl-4-piperidyl ester |
| brn 1555154 |
| 1-methyl-4-piperidyl bis(p-chlorophenoxy)acetate |
| lifibrate (usan/inn) |
| 22204-91-7 |
| D04736 |
| OPREA1_382977 |
| mpca |
| sah 42-348 |
| lifibrate |
| NCGC00160542-01 |
| (1-methylpiperidin-4-yl) 2,2-bis(4-chlorophenoxy)acetate |
| AKOS001637285 |
| y4x961f8z1 , |
| lifibratum |
| lifibrato |
| unii-y4x961f8z1 |
| dtxcid9026217 |
| tox21_111885 |
| cas-22204-91-7 |
| dtxsid1046217 , |
| CHEMBL1883563 |
| lifibrate [usan] |
| lifibrate [inn] |
| MLS006010869 |
| smr004701793 |
| SCHEMBL666775 |
| 1-methyl-4-piperidinyl bis(4-chloro- phenoxy)acetate |
| 1-methyl-4-piperidyl lgyoxylate 2-[bis(p-chlorophenyl)acetal] |
| 1-methyl-4-piperidyl glyoxylate 2-[bis(p-chlorophenyl) acetal] |
| sr-01000945007 |
| SR-01000945007-1 |
| 1-methyl-4-piperidinyl bis(4-chloro-phenoxy)-acetate |
| 2,2-bis(4-chlorophenoxy)-1-methylpiperidin-4-yl acetate |
| Q27294268 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| USP1 protein, partial | Homo sapiens (human) | Potency | 100.0000 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 1.0000 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 16.7855 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 0.2985 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1145557 | Hypolipidemic activity in albino Wistar Royal Hart rat assessed as change in plasma triglyceride level at 30 mg/kg, po for 6 days | 1976 | Journal of medicinal chemistry, May, Volume: 19, Issue:5 | Synthesis and biological evaluation of substituted 2,2'-oxybis(propionic acid) derivatives and related compounds. |
| AID1145550 | Hypolipidemic activity in albino Wistar Royal Hart rat assessed as change in plasma cholesterol level at 30 mg/kg, po for 6 days | 1976 | Journal of medicinal chemistry, May, Volume: 19, Issue:5 | Synthesis and biological evaluation of substituted 2,2'-oxybis(propionic acid) derivatives and related compounds. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||